NephroCheck is a test that tries to determine the risk of some who is seriously sick developing acute kidney injury. Whether or not the test improves outcomes, however, is unclear as of 2016.
NephroCheck tests for the presence of insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) in the urine, which are associated with acute kidney injury. The laboratory test was developed by Astute Medical, in San Diego, California.
References
- ^ FDA. "FDA allows marketing of the first test to assess risk of developing acute kidney injury". www.fda.gov. FDA. Archived from the original on 8 February 2017. Retrieved 2014-09-05.
- Lameire, N; Vanmassenhove, J; Van Biesen, W; Vanholder, R (June 2016). "The cell cycle biomarkers: promising research, but do not oversell them". Clinical Kidney Journal. 9 (3): 353–8. doi:10.1093/ckj/sfw033. PMC 4886923. PMID 27274818.